New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
09:10 EDTELGXEndologix presents data from PEVAR randomized trial
Endologix announced that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach, or PEVAR, to endovascular abdominal aortic aneurysm repair, or EVAR, was recently presented at two medical meetings. Key points from the trial include the primary trial endpoint was met, definitively demonstrating the non-inferiority of PEVAR using the ProGlide closure device to surgical EVAR, a 94% procedural technical success rate was achieved in a multicenter setting, mean procedure time was reduced in PEVAR patients by 34 minutes. Likewise, mean time to hemostasis was reduced following PEVAR by 13 minutes, PEVAR patients required significantly fewer concomitant procedures, favorable trending of PEVAR in several clinical utility outcomes including reduced anesthesia time, reduced blood loss and need for transfusion, shorter hospital length of stay, and less analgesics prescribed for groin pain, and the PEVAR non-inferiority to surgical EVAR persisted through the final 6-month follow-up.
News For ELGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 12, 2015
09:08 EDTELGXEndologix announces FDA approval of AFX 2
Subscribe for More Information
October 9, 2015
08:48 EDTELGXInvestors should look at several medtech stocks, says BMO Capital
BMO Capital believes that macro issues have caused declines in medtech stocks. However, the firm thinks that the sector dealt with pricing issues years ago, while patient volumes are rising and larger cap names in the sector have "relatively stable revenue streams." BMO recommends that investors look at stocks with "reasonable multiples," such as Medtronic (MDT), those with new product pipelines such as Boston Scientific (BSX) and Edwards Lifesciences (EW), and those with small-cap product cycles, including Nevro (NVRO), NuVasive (NUVA), and Endologix (ELGX).
October 7, 2015
08:17 EDTELGXEndologix a stock to own into 2016, says JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use